All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-08-13T07:57:22.000Z

Efficacy and safety analysis of obinutuzumab or rituximab with chemotherapy for previously untreated FL

Aug 13, 2018
Share:

Bookmark this article

On 1st June 2018, a paper on the efficacy and safety outcomes of immunochemotherapy with obinutuzumab (G) or rituximab (R) in previously untreated follicular lymphoma (FL) was published in the Journal of Clinical Oncology by Wolfgang Hiddemann, University Hospital, Ludwig Maximilian University, Munich, and colleagues.

The safety and efficacy analysis came from results of the GALLIUM study (NCT01332968) that compared R and G combined with either cyclophosphamide (C), doxorubicin, vincristine (V) and prednisone (P) (CHOP), CVP or bendamustine.

Study Overview

  • N = 1,202 patients with untreated grade 1–3a FL were included in the study.
  • Patients were randomized 1:1 to receive either G 1,000 mg on Day 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles or R 375mg/m2 on day 1 of 6–8 cycles
    • N = 601 patients received G plus chemotherapy. 47% were male and the median age was 60 years (range, 26–88)
      • N = 345 patients received bendamustine, n = 196 patients received CHOP and n = 60 patients received CVP
    • N = 601 patients received R plus chemotherapy. 47% were male and the median age was 58 years (range, 23–85)
      • N = 341 patients received bendamustine, n = 203 patients received CHOP and n = 57 patients received CVP
    • The primary endpoint was investigator-assessed progression-free survival (INV-PFS)
    • Secondary endpoints included; response rates at end of induction (EOI), overall survival (OS), time-to-next anti-lymphoma treatment (TTNALT) and safety

Key Findings

  • Median follow-up = 41.1 months
  • INV-PFS was significantly longer for G plus chemotherapy (HR, 0.68; 95% CI, 0.54–0.87, P = 0.0016). This was significant across all three arms of chemotherapy, P = 0.75
  • TTNALT was longer for G plus chemotherapy, P = 0.48
  • There was no significant difference in response rates at EOI between the two arms
  • The most frequent adverse events (AEs) grade ≥3 included for G plus chemotherapy included; neutropenia (n = 265), leucopenia (n = 51), febrile neutropenia (n = 42) and infusion-related reactions (n = 40). 42 deaths were reported
  • The most frequent adverse events (AEs) grade ≥3 included for R plus chemotherapy included; neutropenia (n = 226), leucopenia (n = 50), febrile neutropenia (n = 29) and infusion-related reactions (n = 22). 52 deaths were reported

The authors concluded that there was improved efficacy with the G plus chemotherapy treatment arm in patients with previously untreated FL. They noted that cytopenias were reported more frequently with CHOP chemotherapy and more severe infections were reported with bendamustine chemotherapy. Finally, the authors recommended that first-line therapy and subsequent chemotherapy should be considered individually for each patient.

  1. Hiddemann W. et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. Journal of Clinical Oncology. 2018 Jun 1: JCO2017768960. doi: 10.1200/JCO.2017.76.8960. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox